- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00236041
Efficacy/Safety Study of ACTIQ® for Opioid-Tolerant Children and Adolescents With Breakthrough Pain (BTP)
A Double-Blind, Placebo-Comparison Study to Evaluate the Efficacy and Safety of ACTIQ® (Oral Transmucosal Fentanyl Citrate [OTFC®]) Treatment for Opioid-Tolerant Children and Adolescents With Breakthrough Pain
Study Overview
Detailed Description
The primary objective of the study is to evaluate the efficacy of ACTIQ treatment for the management of breakthrough pain (BTP) compared to placebo treatment in children with pain who are receiving around-the-clock (ATC) opioid therapy and who require additional therapy for BTP episodes. This will be determined by the analysis of the pain intensity (PI), measured by the Faces Pain Scale-Revised (FPS-R) administered 15 minutes after the start of each unit of study drug with an optimal ACTIQ dosage.
The secondary objectives are:
- to evaluate the characteristics of BTP in children with pain, including their response to treatment
- to evaluate the efficacy of ACTIQ treatment compared to placebo treatment for these children with regard to time to adequate analgesia by utilizing a stop watch to measure the time for each unit of study drug in the double blind phase
- to evaluate the efficacy of ACTIQ treatment compared to placebo treatment for these children by assessing the occurrence of inadequate analgesia as assessed by the use of rescue medication
- to evaluate the efficacy of ACTIQ treatment compared to placebo treatment for these children by assessing the numbers of patients who withdraw from the study because of inadequate analgesia
- to evaluate the efficacy of ACTIQ treatment compared to placebo treatment for these children by assessing the duration of analgesic effect by using the FPS-R administered at approximately 30, 45, and 60 minutes after the start of each unit of study drug after an optimal dosage is obtained
- to determine the distribution of optimal doses of ACTIQ treatment for these children by age group (3 to under 6 years, 6 to under 11 years, and 11 to under 16 years)
- to establish a safe and effective titration scheme for ACTIQ in these children during the open label phase
- to evaluate the safety of ACTIQ treatment for these children through the assessment of adverse events, clinical laboratory assessments (serum chemistry and hematology), vital sign measurements (including blood pressure, heart rate, and respiration rate), hemoglobin-oxygen saturation level (SpO2, measured via pulse oximetry), electrocardiograms (ECGs), physical examinations, and level of sedation (measured by the University of Michigan Sedation Scale [UMSS])
- to characterize the pharmacokinetics profile of ACTIQ (fentanyl citrate) in these children
- to investigate the exposure and efficacy relationship between plasma concentration of fentanyl and clinical measures of analgesia
Study Type
Enrollment
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
San Juan, Puerto Rico, 00912
- San Jorge Childrens Medical
-
-
-
-
Arkansas
-
Little Rock, Arkansas, United States, 72202
- Children's Hospital of Arkansas
-
-
California
-
Los Angeles, California, United States, 90095
- UCLA Pediatric Pain Program
-
Orange, California, United States, 92868
- Childrens Hospital of Orange
-
Palo Alto, California, United States, 94304
- Lucille Packard Childrens Hospital
-
-
Connecticut
-
Hartford, Connecticut, United States, 06106
- Connecticut Childrens Medical Center
-
-
District of Columbia
-
Washington, District of Columbia, United States, 20010
- Children's National Medical Center
-
-
Florida
-
Jacksonville, Florida, United States, 32207
- Nemours Childrens Clinic
-
Tampa, Florida, United States, 33607
- St. Joseph's Children's Hospital
-
-
Georgia
-
Atlanta, Georgia, United States, 30342
- Scottish Rite Children's Medical Center
-
-
Hawaii
-
Honolulu, Hawaii, United States, 96826
- Kapi'olani Medical Center
-
-
Illinois
-
Chicago, Illinois, United States, 60614
- Children's Memorial Hospital
-
Chicago, Illinois, United States, 60614
- Children's Memorial Center
-
-
Iowa
-
Iowa City, Iowa, United States, 52242
- University Hospitals of Iowa
-
-
Missouri
-
St. Louis, Missouri, United States, 63104
- Cardinal Glennon Children's Hospital
-
-
New Jersey
-
Hackensack, New Jersey, United States, 07601
- Hackensack University Medical Center
-
New Brunswick, New Jersey, United States, 08901
- Cancer Institute of New Jersey
-
-
New Mexico
-
Albuquerque, New Mexico, United States, 87131
- University of New Mexico
-
-
New York
-
Bronx, New York, United States, 10467
- Children's Hospital at Montefiore
-
Syracuse, New York, United States, 13210
- SUNY Upstate Medical University
-
-
North Carolina
-
Durham, North Carolina, United States, 27710
- Duke University Hospital
-
-
Ohio
-
Akron, Ohio, United States, 44308
- Akron Children's Hospital
-
Youngstown, Ohio, United States, 44501
- Tod Children's Hospital
-
-
Pennsylvania
-
Hershey, Pennsylvania, United States, 17033
- Milton S Hershey Medical Center
-
Philadelphia, Pennsylvania, United States, 19134
- St. Christopher's Hospital for Children
-
-
Tennessee
-
Nashville, Tennessee, United States, 37232
- Vanderbilt University Medical
-
-
Texas
-
San Antonio, Texas, United States, 78229
- Methodist Hospital
-
San Antonio, Texas, United States, 78207
- Children's Cancer and Blood Disorders Center
-
-
Washington
-
Spokane, Washington, United States, 99204
- Sacred Heart Medical Center
-
-
West Virginia
-
Morgantown, West Virginia, United States, 99204
- West Virginia University
-
-
Wisconsin
-
Milwaukee, Wisconsin, United States, 53201
- Childrens Hospital of Wisconsin
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Written informed consent of the parent or legal guardian and patient assent, when appropriate, is obtained. (Lack of assent cannot be overturned.)
- The child is aged 3 to under 16 years and weighs at least 15 kg.
- The child must be using ATC opioid therapy for pain associated with cancer and be opioid-tolerant. NOTE: This requirement is defined as the patient receiving at least 1 mg/kg/day or 40 mg/day or more of oral morphine (or an equi-analgesic dosage of another opioid) or at least 25 mcg/hour of transdermal fentanyl for at least 7 days, (ATC opioid therapy may be administered as patient-controlled analgesia [PCA]).
The child must be experiencing episodes of BTP (defined as a transient flare of pain that requires a bolus of medication as treatment) as follows:
- patients with cancer must be experiencing an average of at least 1 BTP episode a day.
- patients with non-cancer related pain must be experiencing an average of 2 BTP episodes a day.
- The child has an average daily pain score of 6 or less (of 10) on the FPS-R.
- Girls who are postmenarche or sexually active must have a negative urine pregnancy test prior to the baseline visit, must be using a medically acceptable method of birth control, and must agree to continue use of this method for the duration of the study (and for 30 days after participation in the study). Acceptable methods of birth control include: barrier method with spermicide; steroidal contraceptive (eg, oral, transdermal, implanted, or injected) in conjunction with a barrier method; intrauterine device (IUD); or abstinence.
- The child, in the opinion of the investigator, is able to administer ACTIQ treatment effectively (ie, adequately moving the unit around in the mouth and sucking, not biting, the unit).
- The child must be an inpatient.
Exclusion Criteria:
- The child has pain uncontrolled by therapy, as determined by the investigator, that could adversely impact the safety of the patient or could be compromised by treatment with ACTIQ.
- The child has known or suspected hypersensitivities/allergies or other contraindications to any ACTIQ component.
- The child has received monoamine oxidase inhibitors (MAOIs) within 14 days before the first ACTIQ treatment.
- The child has moderate to severe oral mucositis.
- The child has a neuromuscular disease, significant renal impairment, or significant hepatic impairment as determined by the investigator.
- The child has any other medical condition or is receiving concomitant medication/therapy that would, in the opinion of the investigator, compromise the patient's safety or compliance with the study protocol, or compromise data collection.
- The child has received any experimental drug/therapy within 14 days of the first ACTIQ treatment. NOTE: Children may not be participating concurrently in another study when the other study requires experimental drug therapy.
- A child's exacerbations of pain are only associated with medical procedures (such as radiation therapy, wound dressing, and bone marrow aspiration).
- The child is receiving any other treatment that, in the opinion of the investigator, could interfere with the pain response.
- For a female patient of childbearing potential: is pregnant or lactating. (Any female patient becoming pregnant during the study will be withdrawn from the study.)
- The child has, in the opinion of the investigator, developmental delay that would interfere with the use of ACTIQ therapy.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Single Group Assignment
- Masking: Double
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
---|
Pain intensity differences as measured by the FPS-R
|
Secondary Outcome Measures
Outcome Measure |
---|
Time to adequate analgesia
|
Duration of analgesia
|
Percentage of BTP episodes requiring rescue medication, or for which oversedation occurs
|
Amount of rescue medication
|
Distribution of optimal doses
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: John Messina, Pharm D, Cephalon, Inc.
Study record dates
Study Major Dates
Study Start
Study Completion
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- C8278b/202/BP/US-CA
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cancer
-
University of Michigan Rogel Cancer CenterRecruitingCancer Liver | Cancer Brain | Cancer Head &Neck | Cancer PelvisUnited States
-
Cellworks Group Inc.RecruitingCancer | Relapsed Cancer | Refractory CancerUnited States
-
Vanderbilt-Ingram Cancer CenterNational Institutes of Health (NIH)Active, not recruitingAdvanced Cancer | Relapsed Cancer | Refractory CancerUnited States
-
UNC Lineberger Comprehensive Cancer CenterHyundai Hope On WheelsRecruitingCancer | Pediatric Cancer | Survivorship | Cancer MetastaticUnited States
-
MiRXES Pte LtdRecruitingBreast Cancer | Gastric Cancer | Colorectal Cancer | Pancreatic Cancer | Esophageal Cancer | Ovarian Cancer | Prostate Cancer | Thoracic Cancer | Liver CancerSingapore
-
Sidney Kimmel Cancer Center at Thomas Jefferson...CompletedStage I Breast Cancer | Stage I Uterine Corpus Cancer | Stage II Uterine Corpus Cancer | Stage III Uterine Corpus Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage... and other conditionsUnited States
-
Massachusetts General HospitalNational Comprehensive Cancer NetworkCompletedGastric Cancer | Pancreatic Cancer | Esophageal Cancer | Rectal Cancer | Colon Cancer | Hepatobiliary CancerUnited States
-
Johns Hopkins UniversityNational Cancer Institute (NCI); National Institute on Minority Health and...Enrolling by invitationCancer | Advanced Cancer | End Stage Cancer | MalignancyUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)CompletedStage III Pancreatic Cancer | Stage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage IV Gastric Cancer | Stage IVA Colorectal Cancer | Stage IVA Pancreatic Cancer | Stage IVB Colorectal Cancer | Stage IVB Pancreatic Cancer | Stage IIIA Gastric Cancer | Stage IIIB Gastric Cancer | Stage IIIC Gastric... and other conditionsUnited States
-
Case Comprehensive Cancer CenterCompletedStage IIA Rectal Cancer | Stage IIB Rectal Cancer | Stage IIC Rectal Cancer | Stage IIIA Rectal Cancer | Stage IIIB Rectal Cancer | Stage IIIC Rectal Cancer | Stage IIIA Colon Cancer | Stage IIIB Colon Cancer | Stage IIIC Colon Cancer | Recurrent Colon Cancer | Recurrent Rectal Cancer | Stage IVA Colon Cancer | Stage IVA Rectal Cancer and other conditionsUnited States
Clinical Trials on ACTIQ®
-
Children's Hospital of PhiladelphiaCompletedCongenital Cystic Adenomatoid MalformationUnited States
-
Nanjing Medical UniversityCompleted
-
Lawson Health Research InstituteUniversity of Western Ontario, CanadaCompletedAnesthetic, Sedative or Analgesic Complications in Labor or DeliveryCanada
-
CephalonCompleted
-
Loyola UniversityUnknownHypotensionUnited States
-
MallinckrodtCompleted
-
Matrix Biomed, Inc.MedStar GeorgetownNot yet recruitingGlioblastoma | Glioblastoma MultiformeUnited States
-
CephalonCompletedPain | Cancer | Sickle Cell Anemia | Severe BurnsUnited States, Canada, Puerto Rico
-
Dong-A ST Co., Ltd.CompletedFunctional DyspepsiaKorea, Republic of
-
Galderma R&DCompletedAtopic DermatitisPhilippines, China